References
1.
Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-440.
2.
Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P: Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97:1925-1928.
3.
Moreau P, Karamanesht I, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, Venkatakrishnan K, Skee D, Feng H, Girgis S, Cakana A, van de Velde H, Deraedt W, Facon T: Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet 2012;51:823-829.
4.
Lamm W, Drach-Schauer B, Eder S, Drach J: Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma. Oncology 2013;85:223-227.
5.
Shah G, Kaul E, Fallo S, Cossor F, Smith H, Sprague K, Klein A, Miller K, Comenzo R: Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther 2013;35:1614-1620.
6.
Liu H, Fu CC, Xue SL, Li WY, Wu Q, Gu B, Jin S, Zhu XM, Zhao SF, Xin X, Ma L, Sun AN, Wu DP: Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novo patients with multiple myeloma (in Chinese). Zhonghua Xue Ye Xue Za Zhi 2013;34:868-872.
7.
Lok A, Mocquard J, Bourcier J, Redelsperger L, Bonnet A, Chauvin C, Thomaré P, Mahé B, Touzeau C, Moreau P: Subcutaneous bortezomib incorporated into the VTD regimen as part of frontline therapy in the context of ASCT for multiple myeloma. Haematologica 2014;99:e33-e34.
8.
Barbee MS, Harvey RD, Lonial S, Kaufman JL, Wilson NM, McKibbin T, Hutcherson DA, Surati M, Valla K, Shah KS: Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. Ann Pharmacother 2013;47:1136-1142.
9.
Mateos MV, San Miguel JF: Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 2012;2:117-124.
10.
Mateos MV: Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 2011;12:410-411.
11.
Lonial S: Is subcutaneous bortezomib ready for prime time? Curr Hematol Malig Rep 2011;6:73-74.
12.
Ohgiya D, Tsuchiya T, Suyama T, Watanabe S, Numata H, Tsuboi K, Sasao T: An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma. Acta Haematol 2015;133:29-30.
13.
Kamimura T, Miyamoto T, Yokota N, Takashima S, Chong Y, Ito Y, Akashi K: Higher incidence of injection site reactions after subcutaneous bortezomib administration on the thigh compared with the abdomen. Eur J Haematol 2013;90:157-161.
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.